Differential effects of the immunosuppressant FK-506 on human α2(I) collagen gene expression and transforming growth factor β signaling in normal and scleroderma fibroblasts

Arthritis and Rheumatism

Volumn 52, Issue 4, 2005, Pages 1237-1247

  Asano, Yoshihide ^a   Ihn, Hironobu ^a,b   Yamane, Kenichi ^a   Jinnin, Masatoshi ^a   Mimura, Yoshihiro ^a   Tamaki, Kunihiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; PROCOLLAGEN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL CULTURE; FIBROBLAST; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NORTHERN BLOTTING; PRIORITY JOURNAL; SCLERODERMA; TRANSCRIPTION REGULATION;

CELLS, CULTURED; COLLAGEN TYPE I; FIBROBLASTS; GENE EXPRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROCOLLAGEN; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

EID: 17244362473     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20934     Document Type: Article

References (46)

1. LeRoy EC. Systemic sclerosis (scleroderma). In: Wyngaarden JB, Smith LH, Bennett JC, editors. Cecil textbook of medicine. 19th ed. Philadelphia: WB Saunders; 1992. p. 1530-5.
2. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53.
3. Van de Water J, Haapanen L, Boyd R, Abplanalp H, Gershwin ME. Identification of T cells in early dermal lymphocytic infiltrates in avian scleroderma. Arthritis Rheum 1989;32:1031-40.
4. Ferrarini M, Steen V, Medsger TA Jr, Whiteside TL. Functional and phenotypic analysis of T lymphocytes cloned from the skin of patients with systemic sclerosis. Clin Exp Immunol 1990;79:346-52.
5. Gruschwitz M, Sepp N, Kofler H, Wick G. Expression of class II-MHC antigens in the dermis of patients with progressive systemic sclerosis. Immunobiology 1991;182:234-55.
6. Abraham D, Lupoli S, McWhirter A, Plater-Zyberk C, Piela TH, Korn JH, et al. Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 1991;34:1164-72.
7. White B. Immunologic aspects of scleroderma. Curr Opin Rheumatol 1995;7:541-5.
8. Chizzolini C, Rezzonico R, Ribbens C, Burger D, Wollheim FA, Dayer JM. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 1998;41:2039-47.
9. Clements PJ, Lachenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A, et al. Cyclosporine in systemic sclerosis: results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993;36:75-83.
10. Morton SJ, Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford) 2000;39:865-9.
11. Levy Y, Sherer Y, Langevitz P, Lorber M, Rotman P, Fabrizzi F, et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin: a preliminary report. Clin Rheumatol 2000;19:207-11.
12. Korn JH. Immunologic aspects of scleroderma. Curr Opin Rheumatol 1989;1:479-84.
13. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974;54:880-9.
14. Jelaska A, Arakawa M, Broketa G, Korn JH. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts: increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 1996;39:1338-46.
15. LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM. A strategy for determining the pathogenesis of systemic sclerosis: is transforming growth factor β the answer? Arthritis Rheum 1989;32:817-25.
16. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 1998;110:47-51.
17. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001;44:474-80.
18. Yamane K, Ihn H, Kubo M, Tamaki K. Increased transcriptional activities of transforming growth factor β receptors in scleroderma fibroblasts. Arthritis Rheum 2002;46:2421-8.
19. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of transforming growth factor (TGF)-β signaling in scleroderma fibroblasts. J Clin Invest 2004;113:253-64.
20. Chen YG, Liu F, Massague J. Mechanism of TGF-β receptor inhibition by FKBP12. EMBO J 1997;16:3866-76.
21. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Increased expression of integrin αvβ5 in scleroderma fibroblasts. Am J Pathol 2004;164:1275-92.
22. Ihn H, Ohnishi K, Tamaki T, LeRoy EC, Trojanowska M. Transcriptional regulation of the human α2(I) collagen gene: combined action of upstream stimulatory and inhibitory cis-acting elements. J Biol Chem 1996;271:26717-23.
23. Ihn H, LeRoy EC, Trojanowska M. Oncostatin M stimulates transcription of the human α2(I) collagen gene via the Sp1/Sp3-binding site. J Biol Chem 1997;272:24666-72.
24. Falanga V, Greenberg AS, Ochoa SM, Roberts AB, Falabella A, Yamaguchi Y. Stimulation of collagen synthesis by anabolic steroid stanozol. J Invest Dermatol 1998;111:1193-7.
25. Brunet CL, Sharpe PM, Ferguson MW. Inhibition of TGF-β3 (but not TGF-β1 or TGF-β2) activity prevents normal and mouse embryonic palate fusion. Int J Dev Biol 1995;39:345-55.
26. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Phosphatidylinositol 3-kinase is involved in α2(I) collagen gene expression in normal and scleroderma fibroblasts. J Immunol 2004;172:7123-35.
27. Okadome T, Oeda E, Saitoh M, Ichijo H, Moses HL, Miyazono K, et al. Characterization of the interaction of FKBP12 with the transforming growth factor-β type I receptor in vivo. J Biol Chem 1996;271:21687-90.
28. Chen CY, Chen TM, Shyu AB. Interplay of two functionally and structurally distinct domains of the c-fos AU-rich elements specifies its mRNA-destabilizing function. Mol Cell Biol 1994;14:416-26.
29. Day DA, Tuite MF. Post-transcriptional gene regulatory mechanisms in eukaryotes: an overview. J Endocrinol 1998;157:361-71.
30. Binder R, Howowitz JA, Basilion JP, Koeller DM, Klausner RD, Harford JB. Evidence that the pathway of transferrin receptor mRNA degradation involves an endonucleolytic cleavage within the 3′ UTR and does not involve poly(A) shortening. EMBO J 1994;13:1969-80.
31. Brown CY, Lagnado CA, Goodall GJ. A cytokine mRNA-destabilizing element that is structurally and functionally distinct from A + U rich elements. Proc Natl Acad Sci U S A 1996;93:13721-5.
32. Stefanovic B, Lindquist J, Brenner DA. The 5′ stem-loop regulates expression of collagen α1(I) mRNA in mouse fibroblasts cultured in a three-dimensional matrix. Nucleic Acids Res 2000;28:641-7.
33. Slack JL, Parker MI, Robinson VR, Bornstein P. Regulation of collagen I gene expression by ras. Mol Cell Biol 1992;12:4714-23.
34. Wang X, Kiledjian M, Weiss IM, Liebhaber SA. Detection and characterization of a 3′ untranslated region ribonucleoprotein complex associated with human α-globin mRNA stability. Mol Cell Biol 1995;15:1769-77.
35. Dornan J, Taylor P, Walkinshaw MD. Structures of immunophilins and their ligand complexes. Curr Top Med Chem 2003;3: 1392-409.
36. Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989;341:758-60.
37. Schreiber SL. Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell 1992;70:365-8.
38. McCaffrey PG, Perrino BA, Soderling TR, Rao A. NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. J Biol Chem 1993;268:3747-52.
39. Jayaraman T, Brillantes AM, Timerman AP, Fleischer S, Tempst P, Marks AR. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem 1992;267:9474-7.
40. Cameron AM, Steiner JP, Sabatini DM, Kaplin AI, Walensky LD, Snyder SH. Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. Proc Natl Acad Sci U S A 1995;92:1784-8.
41. Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasova E, Jayaraman T, et al. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 1994;77:513-23.
42. Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Blazar BR, et al. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996;87:3514-9.
43. Przepiorka D, Nash RA, Wingard JR, Zhu J, Maher RM, Fitzsimmons WE, et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant 1999;5:94-7.
44. Banerji SS, Parsons JN, Tocci MJ. The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. Mol Cell Biol 1991;11:4074-87.
45. Ishibashi M. Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Transplant Proc 1991;23:3071-4.
46. Frizell E, Abraham A, Doolittle M, Bashey R, Kresina T, van Thiel D, et al. FK506 enhances fibrogenesis in in vitro and in vivo models of liver fibrosis in rats. Gastroenterology 1994;107:492-8.